Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NovoThirteen

- PMLiVE

First von Willebrand disease therapy heads new FDA approvals

Baxalta's Vonvendi set for an early 2016 launch in the US

- PMLiVE

Novo Nordisk says Victoza outperforms SGLT2 inhibitors

Comparesthe GLP-1 agonist to Invokana, Jardiance and Farxiga

- PMLiVE

PMEA 2015 win for Novo’s Changing Diabetes in Children

Company wins the EY Award for SociallyResponsible Initiatives

EU flag

Wakix backed for European approval in narcolepsy

Bioprojet Pharma’s orphan drug given a positive opinion by CHMP

- PMLiVE

Novo Nordisk finally bags insulin degludec approval in US

Aims to get Tresiba and Ryzodeg back on course 

Novo launches online news channel for haemophilia patients

New medical information website aims to be a 'simple, centralised repository'

- PMLiVE

Novo Nordisk appoints new senior principal clinical scientist

Stephen Gough joins the Danish diabetes giant

- PMLiVE

New data arms Novo Nordisk for insulin battle with Sanofi

Tresibaand Xultophy boosted by studies presented at EASD 

- PMLiVE

Orphan drug firm Sobi opens new European base

Company'sBrussels office will also house its Benelux operations

- PMLiVE

Novo collaborates with MIT on next-gen drug delivery devices

Aims to create new delivery vehicles for administration of peptides

- PMLiVE

Novo Nordisk acquires two US biopharma companies

Strikes deals with Calibrium LLC and MB2

- PMLiVE

Novo Nordisk plans $2bn expansion of its diabetes facilities

Comes as the Danish firm prepares to move oral semaglutideinto phase III trials

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links